Cellectis (CLLS) Net Cash Flow (2015 - 2026)
Cellectis (CLLS) posted quarterly Net Cash Flow of -$26.5 million for Q1 2026, down 55.49% year-over-year from -$59.5 million in Q1 2025, and down 432.98% quarter-over-quarter from $8.0 million in Q4 2025.
Cellectis (CLLS) Net Cash Flow (2015 - 2026) Analysis & Trends
Cellectis' Net Cash Flow history runs 12 years deep, the most recent figure standing at -$26.5 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 55.49% year-over-year to -$26.5 million; the TTM figure through Mar 2026 stood at -$95.1 million (down 1757.56% YoY), while the FY2025 annual figure was -$85.6 million, down 1021.52% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$26.5 million, down from $8.0 million in the prior quarter.
- The five-year high for Net Cash Flow was $67.6 million in Q4 2023, with the low at -$67.3 million in Q2 2025.
- The 5-year median for Net Cash Flow is -$13.8 million (2024), against an average of -$9.3 million.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow jumped 2538.29% in 2024, then sank 377.39% in 2025.
- Cellectis' Net Cash Flow stood at -$15.6 million in 2022, then surged by 532.45% to $67.6 million in 2023, then sank by 120.38% to -$13.8 million in 2024, then soared by 157.69% to $8.0 million in 2025, then tumbled by 432.98% to -$26.5 million in 2026.
- Business Quant data shows CLLS's Net Cash Flow at -$26.5 million in Q1 2026, $8.0 million in Q4 2025, and -$9.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | -26.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.48 Mn |
| Mar 31, 2026 | -26.48 Mn |
| Dec 31, 2025 | 7.95 Mn |
| Dec 31, 2025 | 7.95 Mn |
| Sep 30, 2025 | -9.27 Mn |
| Sep 30, 2025 | -9.27 Mn |
| Jun 30, 2025 | -67.30 Mn |
| Jun 30, 2025 | -67.30 Mn |
| Mar 31, 2025 | -17.03 Mn |
| Mar 31, 2025 | -17.03 Mn |
| Dec 31, 2024 | -13.78 Mn |
| Dec 31, 2024 | -13.78 Mn |
| Sep 30, 2024 | 12.29 Mn |
| Sep 30, 2024 | 12.29 Mn |
| Jun 30, 2024 | 24.26 Mn |
| Jun 30, 2024 | 24.26 Mn |
| Mar 31, 2024 | -13.47 Mn |
| Mar 31, 2024 | -13.47 Mn |
| Dec 31, 2023 | 67.64 Mn |
| Dec 31, 2023 | 67.64 Mn |